Bionomics Ltd (ASX:BNO) (OTCMKTS:BNOEF) (FRA:B1N) has completed the MODULATE clinical trial, an experimental phase 2 trial of its drug candidate BNC105 in combination with Bristol Myers Squibb’s (NYSE:BMY) nivolumab, in patients with metastatic colorectal cancer.
The trial sponsor, the Australasian Gastro-Intestinal Trials Group (AGITG), is expecting that results will be ready in the second quarter of 2021, which is ahead of the previously announced timeline for topline data of early 2023.
Bionomics executive chairman Dr Errol De Souza said: “We thank AGITG, the trial sponsor, and the patients who participated in the study, and look forward to reporting the topline data in Q2 2021.”
The MODULATE trial
AGITG is conducting the MODULATE trial to evaluate new experimental approaches to immunotherapy treatment in colorectal cancer patients.
In one arm of the trial, it is investigating whether Bionomics’ drug candidate BNC105, a vascular disrupting agent, combined with nivolumab, a PD-1 (programmed death-1) immune checkpoint inhibitor, can be used to treat advanced colorectal cancer patients who have exhausted other treatment options.
A second group of patients are receiving nivolumab in combination with a Signal Transduction Activator of Transcription (STAT3) inhibitor.
Bionomics is a global, clinical-stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates.